Richter Gedeon stock has results due November 10, 2026

Published on 10/16/2026 at 15:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached HUF 151.8 billion in first-half 2026, up 3.00 percent. Richter Gedeon stock costs EUR 34.67 on October 16, 2026 at Lang & Schwarz.

Upcoming results and valuation

Yahoo Finance lists November 10, 2026 as the next earnings date for Richter Gedeon.
First-half 2026 revenue reached HUF 151.8 billion, up 3.00 percent year over year.
Richter Gedeon stock costs EUR 34.67 at Lang & Schwarz on October 16, 2026 at 2:59 p.m. CEST.
Richter Gedeon had a P/E ratio of 9.99 on October 15, 2026.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Yahoo Finance lists November 10, 2026 as the next earnings date for Richter Gedeon stock. That scheduled report is the next clear calendar point for investors tracking the Hungarian pharmaceutical company.

The latest reported operating figure points to measured growth. In the first half of 2026, revenue reached HUF 151.8 billion, up 3.00 percent year over year, according to Yahoo Finance. The same source described foreign-exchange headwinds in the reporting period, making the constant-currency performance relevant when the company updates investors.

Revenue growth shapes the next report

Richter Gedeon's first-half revenue growth provides the main operating benchmark for the November report. The HUF 151.8 billion figure covers the six months ended June 30, 2026, while the 3.00 percent comparison is measured against the same period of 2025. The company published its H1 2026 earnings presentation on August 7, 2026, on its investor page.

Price position and valuation

At 2:59 p.m. CEST on October 16, 2026, Richter Gedeon stock was at EUR 34.67 at Lang & Schwarz. The bid was EUR 34.40 and the ask was EUR 34.94, giving investors a live spread of EUR 0.54. These levels describe the German euro quotation rather than the company's Budapest share price.

RGEDF was quoted at USD 38.63 on October 15, 2026, with a 52-week range of USD 29.00 to USD 45.28. The market capitalization was USD 7.1 billion and the P/E ratio was 9.99 on that quotation, while the trailing dividend yield was 0.05 percent. The valuation figures provide a separate reference point because the quotation currency differs from the euro price.

As of October 16, 2026, Bayer traded at EUR 44.26, down 0.34 percent, with a P/E ratio of minus 25.15 and a market capitalization of EUR 43.5 billion. Teva traded at USD 41.11, up 0.96 percent, with a P/E ratio of 69.08 and a market capitalization of USD 47.9 billion.

Comparison with peers

Richter Gedeon: P/E 9.99, market capitalization USD 7.1 billion.

Bayer (Xetra, EUR): minus 0.34 percent, P/E minus 25.15, market capitalization EUR 43.5 billion.

Teva (NYSE, USD): plus 0.96 percent, P/E 69.08, market capitalization USD 47.9 billion.

What investors can quantify next

The November 10, 2026 reporting date gives the market a defined checkpoint for revenue, earnings and management commentary. Until then, the first-half revenue base of HUF 151.8 billion and the 3.00 percent year-over-year increase remain the clearest operating markers. The euro quotation stood at EUR 34.67 at Lang & Schwarz on October 16, 2026 at 2:59 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.